Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD 0360324 in Chronic Pulmonary Sarcoidosis
NCT01732211Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Mar 2013
- Primary completion
- Sep 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary sarcoidosis comparing PD 0360324 with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 16 weeks. Started Mar 2013; status: terminated.
02
Drugs
PD-0360324
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT01732211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732211.